Intarcia Therapeutics
| Type | Private |
|---|---|
| Industry | pharmaceutical industry |
| Founded | Hayward, California, United States (1995) |
| Headquarters | Hayward, California, United States |
| Key people |
|
| Products | (none as of 2012) |
| Website | www.intarcia.com |
Intarcia Therapeutics is an American pharmaceutical company based in Hayward, California and incorporated under the laws of Delaware.[1][2] It was founded in 1995 under the name "BioMedicines" and changed to its present name in 2004.[1] In April 2012, the company announced its intention to relocate its headquarters to the Boston-area.[6]
In 2005, the executive leadership of Intarcia was largely vested in two people, Karling Leung and James Ahlers, President/CEO/Director and Vice President/CFO/Finance & Operations Officer, respectively.[4] By 2012, Kurt Graves had replaced Karling Leung as President and CEO.[5]
As of 2012[update], Intarcia is engaged in development of a "potential once-a-year type 2 diabetes treatment". Referred to as ITCA-650, the therapeutic consists of exenatide delivered via its DUROS system,[7] "a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides".[1]
Notes
- ^ a b c d "Company Overview of Intarcia Therapeutics, Inc.", Bloomberg Businessweek, retrieved November 15, 2012
- ^ a b Exhibit 4.1, SEC, retrieved November 15, 2012
- ^ Radius Health, Inc. (FORM S-1), SEC, February 6, 2012, retrieved November 15, 2012
- ^ a b "INTARCIA THERAPEUTICS, INC.", AMENDMENT NO. 1 TO FORM S-1 (SEC), March 18, 2005, retrieved November 15, 2012
- ^ a b Ron Leuty (November 15, 2012), "Intarcia raises $210M as it pushes once-a-year diabetes treatment into Phase III, moves HQ to Boston area", San Francisco Business Times, retrieved November 15, 2012
- ^ Don Seiffert (November 15, 2012), "Intarcia, in midst of move to Boston, raises $210M", Mass High Tech (American City Business Journals), retrieved November 15, 2012
- ^ "Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus", ClinicalTrials.gov, May 1, 2012, retrieved November 15, 2012
 |
This corporation or company article is a stub. You can help Wikipedia by expanding it. |
